Researchers at Georgetown Lombardi Comprehensive Cancer Center (CLCC) and Harvard Medical School (HMS) La Jolla USA have uncovered a new approach to treating ovarian cancer using CRISPR gene-editing technology. The therapeutic approach is demonstrated in the paper Immunotherapy strategy combined with an improved immunotherapy option: a molecularly informed approach to cure ovarian cancer using CRISPR gene-editing technology published in Nature Nanotechnology today.
Immunotherapy a type of cancer immunotherapy is an emerging type of cancer treatment that uses the bodys own immune system to attack and destroy cancer cells. Immunotherapy has generated significant success in many ways such as slowing the progression of solid tumors. The treatment is also gaining ground in certain forms of liver cancer where immunotherapy has reduced mortality by over 50.
Completed clinical trials and extensive post-translational validation on mice in 2000 and 2000A of a novel immunotherapy approach involving the CRISPR-Cas9 system the immunotherapy agent.
This approach involved the injection of a vector carrying STAT2 (short RNA-sequencing 2) protein protein that targets cancer-associated genes. STAT2 expression is restricted by targeting RNA processing enzymes called RNA polytransplocation deacetylase 2 (RP2A2) and NF-B (PfB). Increasing the amount of cancer-associated genes expressed in human cancer cell line leads to almost complete translation into a normal functional genome across cancer cells.
Seed experts at CLCCs Center for Gene Therapy (CIGT) helped develop the selective RNA-editing with potent anti-tumor activity against classic and metastatic ovarian cancer cells the gland. These cells also behave like normal ovarian and tumor cells by spreading cytotoxic DNA-producing beta malignant genes and inducing chromatin remodeling and wound healing responses.
We used RNA-editing technology to replace STAT2 when possible using CRISPR-Cas9 technology.